Skin & Matrix
Goal · Dermal collagen synthesis + tissue-remodeling research.
GHK-Cu drives transcriptional upregulation of collagen, elastin, and glycosaminoglycan synthesis in dermal fibroblasts. BPC-157 contributes VEGF-driven angiogenesis to support the new matrix. The combination is common in cosmetic-research community protocols, particularly for topical + subcutaneous co-application. Per-component literature applies independently.
COMPONENTS
Collagen + elastin + GAG induction (skin matrix)
VEGF angiogenesis to support new matrix
CYCLE FRAMING
8–12 weeks topical + subcutaneous community protocols
RESEARCH NOTE
Topical 0.05–0.1% GHK-Cu has peer-reviewed cosmetic-trial data. Injectable GHK-Cu is research-use only.
SOURCED FROM PEPPU LABS
Each component is available individually as research-grade material at Peppu Studio · ≥99% purity · per-batch CoA. For laboratory research use only. No human dose is recommended.
SOURCE COMPONENTS ▶